Versant Venture Management, LLC Long-Term Concentrated

Location: San Francisco, CA

CIK: 0001560009 · Show all filings

Period: Q1 2026 (← Previous) (Next →)

Filing Date: May 5, 2026

Total Value: $141M (100.0% shares, 0.0% debt)

Holdings (8)

GLUE Monte Rosa Therapeutics, Inc. 37.0%

Value $52.32M Shares 3,180,780 Est. Cost $7.50 Unrealized +175.3%

IPSC Century Therapeutics, Inc. 19.4%

Value $27.5M Shares 12,166,109 Est. Cost $1.94 Unrealized 0.0%

LENZ Lenz Therapeutics, Inc. 17.2%

Value $24.31M Shares 2,656,888 Est. Cost $36.77 Unrealized -57.2%

JBIO Jade Biosciences, Inc. 15.2%

Value $21.44M Shares 1,525,820 Est. Cost $33.31 Unrealized -55.6%

CTNM Contineum Therapeutics, Inc. 5.0%

Value $7.087M Shares 542,628 Est. Cost $16.10 Unrealized -17.1%

CRSP CRISPR Therapeutics AG 5.0%

Value $7.08M Shares 148,831 Est. Cost $40.26 Unrealized +32.9%

SKYE Skye Bioscience, Inc. 0.9%

Value $1.234M Shares 2,007,704 Est. Cost $7.75 Unrealized -88.5%

— Tempest Therapeutics, Inc. 0.3%

Value $442K Shares 269,772 Est. Cost $6.80 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
GLUE	Monte Rosa Therapeutics, Inc.	3,180,780	$52.32M	37.0%	$7.50	+175.3%	Common Stock	61225M102
IPSC	Century Therapeutics, Inc.	12,166,109	$27.5M	19.4%	$1.94	0.0%	Common Stock	15673T100
LENZ	Lenz Therapeutics, Inc.	2,656,888	$24.31M	17.2%	$36.77	-57.2%	Common Stock	52635N103
JBIO	Jade Biosciences, Inc.	1,525,820	$21.44M	15.2%	$33.31	-55.6%	Common Stock	008064206
CTNM	Contineum Therapeutics, Inc.	542,628	$7.087M	5.0%	$16.10	-17.1%	Common Stock	21217B100
CRSP	CRISPR Therapeutics AG	148,831	$7.08M	5.0%	$40.26	+32.9%	Common Shares	H17182108
SKYE	Skye Bioscience, Inc.	2,007,704	$1.234M	0.9%	$7.75	-88.5%	Common Stock	83086J200
—	Tempest Therapeutics, Inc.	269,772	$442K	0.3%	$6.80	—	Common Stock	87978U108